治疗与未治疗甲状腺功能亢进症中的超额死亡率与血清TSH降低累积时间相关
基于登记数据的队列研究纳入235,547名1995至2011年间至少检测一次血清TSH者(中位随访7.3年),甲亢定义为至少两次低TSH。未治疗甲亢患者死亡率风险升高(HR 1.23),治疗者未升高;TSH降低每累积6个月,未治疗与治疗患者死亡HR分别为1.11和1.13。
要点
- 未治疗甲亢患者死亡风险升高(HR 1.23;95%CI 1.12–1.37;P<0.001),治疗者未见升高。
- TSH降低每累积6个月,未治疗者死亡HR 1.11(95%CI 1.09–1.13),治疗者HR 1.13(95%CI 1.11–1.15)。
- TSH降低5年后,未治疗与治疗甲亢患者死亡率分别增加184%和239%。
核心结论
- 甲亢患者死亡率升高,TSH降低累积时间在治疗与未治疗甲亢中均增加死亡风险,提示超额死亡可能并非源于缺乏治疗,而是无法维持甲状腺功能正常。
研究设计与样本
- 基于登记数据的队列研究,纳入235,547名1995至2011年间至少有一次血清TSH检测者,中位随访7.3年,甲亢定义为至少两次低血清TSH。
主要发现
- 未治疗甲亢患者死亡HR为1.23(95%CI 1.12–1.37;P<0.001),治疗甲亢患者未见死亡率升高。
- TSH降低每累积6个月,未治疗甲亢患者(n=1137)死亡HR为1.11(95%CI 1.09–1.13;P<0.0001),治疗患者(n=1656)HR为1.13(95%CI 1.11–1.15;P<0.0001)。
- TSH降低5年后,未治疗与治疗甲亢患者死亡率分别增加184%和239%。
临床怎么用
- 作者认为,治疗期间细致随访以维持生化甲状腺功能正常可能是必要的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND AIM: Cumulative time-dependent excess mortality in hyperthyroid patients has been suggested. However, the effect of antithyroid treatment on mortality, especially in subclinical hyperthyroidism, remains unclarified. We investigated the association between hyperthyroidism and mortality in both treated and untreated hyperthyroid individuals. PATIENTS AND METHODS: Register-based cohort study of 235,547 individuals who had at least one serum thyroid-stimulating hormone (TSH) measurement in the period 1995 to 2011 (7.3 years median follow-up). Hyperthyroidism was defined as at least two measurements of low serum TSH. Mortality rates for treated and untreated hyperthyroid subjects compared with euthyroid controls were calculated using multivariate Cox regression analyses, controlling for age, sex, and comorbidities. Cumulative periods of decreased serum TSH were analyzed as a time-dependent covariate. RESULTS: Hazard ratio (HR) for mortality was increased in untreated [1.23; 95% confidence interval (CI), 1.12 to 1.37; P < 0.001], but not in treated, hyperthyroid patients. When including cumulative periods of TSH in the Cox regression analyses, HR for mortality per every 6 months of decreased TSH was 1.11 (95% CI, 1.09 to 1.13; P < 0.0001) in untreated hyperthyroid patients (n = 1137) and 1.13 (95% CI, 1.11 to 1.15; P < 0.0001) in treated patients (n = 1656). This corresponds to a 184% and 239% increase in mortality after 5 years of decreased TSH in untreated and treated hyperthyroidism, respectively. CONCLUSIONS: Mortality is increased in hyperthyroidism. Cumulative periods of decreased TSH increased mortality in both treated and untreated hyperthyroidism, implying that excess mortality may not be driven by lack of therapy, but rather inability to keep patients euthyroid. Meticulous follow-up during treatment to maintain biochemical euthyroidism may be warranted.
引用
- Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, et al. Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH. J Clin Endocrinol Metab. 2017. PMID: 28368540. doi:10.1210/jc.2017-00166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。